RemeGen (PK)【REGMF】銘柄情報

RemeGen Company Ltd (PK) (REGMF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

9.50

( - )

買値

10.30

売値

11.38

出来高

平均取引量 (3 か月)

US$ 4,512,419

財務取引量

0.00 日の範囲 0.00

5.06 52 週間の範囲 15.91

時価総額

5.32B

企業価値

67.656B

前日終値

9.50

始値

時刻

最終取引時間

VWAP

歳入

3.38B

純利益

1.29B

発行済株式数

559,970,290

浮動株比率 (%)

61.47%

機関投資家保有比率 (%)

26.49%

配当利回り

PER

32.55

株価売上高倍率 (PSR)

20.2

1 株当たり利益 (EPS)

2.33

ベータ

0.44

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus er... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China. 詳細を表示

セクター

業界

ウェブサイト

www.remegen.com

本社

Yantai, China

設立

2026

RemeGen Company Ltd (PK) is listed in the sector of the その他OTC with ticker REGMF. The last closing price for RemeGen (PK) was US$9.50. Over the last year, RemeGen (PK) shares have traded in a share price range of US$ 5.06 to US$ 15.91.

RemeGen (PK) currently has 559,970,290 shares in issue. The market capitalisation of RemeGen (PK) is US$5.32 billion. RemeGen (PK) has a price to earnings ratio (PE ratio) of 32.55.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	-1.4491	-13.2348777525	10.9491	12.85	9.5	750	12.64777778	CS
26	-0.31	-3.16004077472	9.81	12.85	9.5	682	11.71194	CS
52	4.44	87.7470355731	5.06	15.91	5.06	3874	5.80551867	CS
156	5.4	131.707317073	4.1	15.91	1.5	2896	5.61336568	CS
260	-6.13	-39.2194497761	15.63	15.91	1.5	2603	6.20992719	CS